Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accumulated Expenses (2016 - 2025)

Ptc Therapeutics (PTCT) has 12 years of Accumulated Expenses data on record, last reported at $9.6 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 84.45% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, down 84.45%, while the annual FY2025 figure was $9.6 million, 84.45% down from the prior year.
  • Accumulated Expenses reached $9.6 million in Q4 2025 per PTCT's latest filing, down from $49.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $62.6 million in Q4 2023 and bottomed at $500000.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $34.7 million, with a median of $37.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 5797.0% in 2022, then tumbled 84.45% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $55.7 million in 2021, then fell by 27.25% to $40.5 million in 2022, then skyrocketed by 54.5% to $62.6 million in 2023, then fell by 1.7% to $61.6 million in 2024, then crashed by 84.45% to $9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $9.6 million in Q4 2025, $49.5 million in Q3 2025, and $38.2 million in Q2 2025.